Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
157 hedge funds and large institutions have $1.71B invested in Global Blood Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 51 reducing their positions, and 26 closing their positions.
81% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 26
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
70% more call options, than puts
Call options by funds: $49.5M | Put options by funds: $29.1M
40% more capital invested
Capital invested by funds: $1.22B → $1.71B (+$486M)
15% more funds holding
Funds holding: 136 → 157 (+21)
4% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$60.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.2M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$29.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$26.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$67.1M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$13.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.7M |
| 5 |
O
OrbiMed
New York
|
-$8.81M |
GBT Hedge Fund Activity: Q4 2017 in Review
157 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2017, worth a combined $1.71B — up 40% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new GBT positions and 26 closed out — a net gain of 21 holders — while 49 added to existing stakes and 51 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $60.3M. The largest seller was Point72 Asset Management, cutting an estimated $67.1M.
- 157 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2017, up from 136 in Q3 2017.
- Funds reported $1.71B of Global Blood Therapeutics, Inc. stock for Q4 2017, up 40% quarter-over-quarter.
- 47 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2017 and 26 closed out, a net change of +21 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2017 was Janus Henderson Group, an estimated $60.3M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2017 was Point72 Asset Management, an estimated $67.1M sold.
Based on aggregated 13F filings for Q4 2017.